Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) Signals for Healthy Controls Evoked Response Potential (ERP) Signals for Healthy Controls and Patients With Parkinson Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02149498

Enrollment

100

Registered

2014-05-29

Start date

2014-07-31

Completion date

2016-07-31

Last updated

2014-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson, EEG, BNA

Brief summary

A cornerstone in PD research is the investigation of neurophysiological changes as potential biomarkers that could help in tracking disease progression and response to therapies. Electroencephalography (EEG) could provide a non-invasive and relatively cheap tool for identification of such biomarkers. In this study we will use high-density electroencephalograph (EEG) recording, in order to develop a platform of biomarkers that could be more sensitive and reliable to disease progression and response to therapeutic intervention than standard clinical measures.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

1. Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause) and HC aged 40-80 years 2. PD patients Hoehn and Yahr stages I to IVStable PD therapy

Exclusion criteria

* In the investigator's opinion, any unstable or clinically significant condition that would impair the participants' ability to comply with study requirements. * Patients or HC with significant psychiatric symptoms or history * BDI score \<14 * MMSE \<25 * Treatment with neuroleptics. * For PD patients: Hoehn and Yahr Stage 5 * PD Patients with severe dyskinesia or tremor * PD Patients with atypical Parkinsonism or secondary Parkinsonism * History or evidence of neurological problems: cerebrovascular disease, previous head injury or neurosurgical interventions. * Currently with lice or open wounds on scalp. * Significant sensory deficits, e.g., deafness or blindness * Current drug abuse or alcoholism. * Pregnancy or not using a reliable method of birth control. * Participation in current clinical study or clinical study within 30 days prior to this study.

Design outcomes

Primary

Measure	Time frame	Description
Functional networks of brain activity in Idiopathic PD patients and healthy individuals measured using analysis of EEG Event Related Potential	2 WEEKS	The study outcome measure are functional networks of brain activity of PD patients and healthy individuals established based on an analysis of EEG data recorded while study subjects perform ERP tasks

Contacts

Primary ContactNaama Warman Alaluf, Msc

naama.warmanalaluf@sheba.health.gov.il972-3-530-4931

Outcome results